Skip to main content
Premium Trial:

Request an Annual Quote

Mirna Begins Enrolling Hematological Cancer Patients in microRNA Drug Trial


NEW YORK (GenomeWeb) – Mirna Therapeutics this week announced that it has begun enrolling patients with hematological malignancies in an ongoing Phase I trial of its microRNA-based cancer treatment MRX34.

The drug is a synthetic version of miR-34a, a miRNA known to play a role in the p53 tumor-suppressor pathway, that is formulated with Marina Biotech's Smarticle liposomal delivery technology.

In mid-2013, the drug entered clinical testing in patients with primary liver cancer or advanced metastatic cancer, including lymphoma, with liver involvement. As patients were enrolled in the study, Mirna was also evaluating other cancer indications that it might include in the trial, eventually settling on hematological malignancies.

In April, Mirna unveiled interim data of 26 solid tumor patients from the study, showing that the drug had a "manageable safety profile."

With the maximum tolerated dose of MRX34 yet to be identified, the trial will enroll up to 48 liver cancer patients and 15 hematological cancer patients who will receive escalating doses of the drug until disease progression or intolerance.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.